Novocellbio Launches Full-Scale Clinical Trials of NK Cell Therapy in Mexico

Monterrey Zambrano Hellion Hospital, Mexico

[Asia Economy Reporter Chunhee Lee] Novocell Bio announced on the 12th that it has completed the NK cell culture experiment of Novocell Bio's NK cell therapy (NOVO-NK) conducted at Monterrey Zambrano Hellion Hospital to obtain final clinical trial approval from Mexico's Texsalud and the Mexican Food and Drug Administration, and will commence full-scale clinical trials.

The two companies previously completed a cell therapy manufacturing facility within Zambrano Hellion Hospital last month. Sara Gonzalez, spokesperson for Texsalud, stated that they will start full-scale clinical trials and patient treatment in both countries in connection with Novocell Bio's biopharmaceutical manufacturing facility in Korea.

First, clinical trials for COVID-19 will begin in the first half of this year, followed by additional clinical trials for breast cancer in the second half. Subsequently, they plan to expand the indications.